Stock screener

AKTS

Conviction 20HealthcareScan · Thu, Sep 24, 2026

Aktis Oncology, Inc. (AKTS) closed at $19.64 (-0.41%) on Sep 24, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 29, RS Rating 12, -70.2% from its 52-week high, -12.3% year to date. Sector: Healthcare · Biotechnology.

AKTS$19.64-0.41%
ResistanceSupportVol 14Insider sell
63 bars
6
Vol MA14 637.53K
Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24
Aktis Oncology, Inc.Biotechnologywww.aktisoncology.com ↗
Price19.64
Change-0.41%
Gap+1.37%
Rel volume2.37×
Avg volume515.11K
Avg $ vol11.67M
SMA 2023.84
SMA 5024.03
SMA 20024.82
Price vs 50-18.27%
Price vs 200-20.88%
MA stackbearish
50/200 cross—
Supertrenddown · 23.88
RSI (14)29
MACD hist-0.51
MACD cross—
Stoch %K / %D3 / 8
ADX (14)23
+DI / −DI14 / 34
RSI divergenceBearish
MACD divergenceBearish
ATR %7.05%
ADR %5.59%
52w high66.00
52w low15.19
From 52w high-70.24%
Above 52w low+29.30%
New 52w highNo
SqueezeOff
Bollinger width37.44%
%B0.03
Donchian pos2.55%
Donchian high27.66
Donchian low19.43
AVWAP (52w high)22.96
vs AVWAP high-14.48%
AVWAP (52w low)23.53
vs AVWAP low-16.54%
OBV trendDown
Chaikin MF (20)-0.39
Today vs 20d2.37×
Avg vol (14d)637.53K
Avg vol (20d)515.11K
Avg $ vol (20d)11.67M
Market cap1.05B
RS Rating12 / 99
RS 3m (vs SPY)-41.44%
RS 6m (vs SPY)-11.45%
RS line new highNo
Trend template0/8
Technical rank27.8
1 week-14.09%
1 month-26.41%
3 months-36.95%
6 months+5.36%
1 year-61.26%
YTD-12.32%
P/E—
P/B2.17
P/S—
P/FCF—
EPS—
Div yield—
ROE—
ROA—
Debt/Eq—
Current16.33
EV/EBITDA—
Gross margin—
Net margin—
Rev growth—
EPS growth—
Price target35.80
Target upside82.28%
Analyst ratingBuy
Institutional66.26%
Ent. value967.19M
Revenue3.38M
Net income-24.14M
Gross profit—
Free cash flow—
IndustryBiotechnology
ExchangeNasdaq
Shares out53.4M
Employees79
ListedFri, Jan 9, 2026
Free float23M
Float %43.1%
Short interest3.18M
Days to cover10.4d
Short volume65.7%
Squeeze score85 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.44 vs −$0.44
Last surprise0.0% beat
Setup gradeD
Conviction20 / 100
Pattern quality—
Tech rank27.8 / 100
Group rank59 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance27.42
Support21.77
Days since event—
Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Recent news

Congress activity

Disclosed STOCK Act trades in AKTS

All disclosures →
No recent disclosed trades by Congress in AKTS. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in AKTS · open-market 6 sells

InsiderSideShares
Czibere Akos
Chief Medical Officer · Common Stock · 2026-07-08
Exercise50K
Czibere Akos
Chief Medical Officer · Common Stock · 2026-07-08
Sell14.8K
Czibere Akos
Chief Medical Officer · Common Stock · 2026-07-08
Sell30.83K
Czibere Akos
Chief Medical Officer · Common Stock · 2026-07-08
Sell4.37K
Czibere Akos
Chief Medical Officer · Stock Option (Right to Buy) · 2026-07-08
Exercise50K
Ron-Bigger Shulamit
Chief Operating Officer · Common Stock · 2026-07-08
Exercise50K
Ron-Bigger Shulamit
Chief Operating Officer · Common Stock · 2026-07-08
Sell15.8K
Ron-Bigger Shulamit
Chief Operating Officer · Common Stock · 2026-07-08
Sell30K
Ron-Bigger Shulamit
Chief Operating Officer · Common Stock · 2026-07-08
Sell4.2K
Ron-Bigger Shulamit
Chief Operating Officer · Stock Option (Right to Buy) · 2026-07-08
Exercise50K

SEC filings

EDGAR filings in AKTS · 7 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.